Back to top

Image: Bigstock

Intuitive Surgical (ISRG) Down 1.7% Since Last Earnings Report: Can It Rebound?

Read MoreHide Full Article

A month has gone by since the last earnings report for Intuitive Surgical, Inc. (ISRG - Free Report) . Shares have lost about 1.7% in that time frame, outperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Intuitive Surgical due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Intuitive Surgical, Inc. before we dive into how investors and analysts have reacted as of late.

ISRG Q3 Earnings Rise on Procedure Growth Despite Litigation Charge

Intuitive Surgical reported third-quarter 2026 adjusted earnings of $3.00 per diluted share, up from $2.40 a year earlier, while revenue rose 22% to $3.05 billion.

Worldwide da Vinci procedures increased approximately 14% and Ion procedures rose 31%. Reported earnings fell to $1.49 per diluted share from $1.95, reflecting a substantial litigation charge. While earnings beat Zacks Consensus Estimate by 14.9%, sales beat the estimates by 5.8%.

ISRG Instruments Revenue Tracks Procedure Growth

Instruments and accessories revenue increased 18% to $1.80 billion from $1.52 billion in the prior-year quarter. Higher use of da Vinci systems and Ion contributed to sales, alongside the mix of da Vinci 5 and single-port instruments.

Approximately 906,000 da Vinci procedures were completed during the quarter, compared with about 797,000 a year earlier. U.S. procedure growth of about 10% was lower than growth of about 20% outside the United States. General surgery remained a principal contributor, while domestic bariatric procedures declined at a low-double-digit rate.

Intuitive Surgical Placements Benefit From New Generation

Systems revenue reached $769.1 million compared with $590.4 million a year earlier. Da Vinci placements rose to 546 systems from 427, including 315 da Vinci 5 systems. The larger installed base also supported operating lease revenue.

Of the quarter's placements, 291 da Vinci systems were under operating leases, including 160 usage-based arrangements. These transactions can reduce the initial purchase burden for hospitals but create different revenue-recognition patterns from outright system purchases. Ion placements totaled 56 systems versus 50 a year earlier.

ISRG Services Expand With the Installed Base

Service revenue increased to $482.2 million from $395.9 million a year earlier, benefiting from a larger population of da Vinci and Ion systems that require ongoing support. The da Vinci installed base reached 12,094 units, up 12% year over year.

Ion's installed base was 1,152 systems, up 21%. The combination of a growing installed base and greater procedure activity helps expand the addressable recurring-services opportunity, although maintenance revenue patterns vary with equipment mix and the terms of customer agreements.

Intuitive Surgical Adjusted Profit Contrasts With GAAP

Adjusted gross profit increased to $2.13 billion from $1.70 billion, and the adjusted gross margin expanded to 69.9% from 68%. Adjusted operating income rose to $1.27 billion from $975.9 million, reflecting sales growth and operating leverage.

Reported operating income nevertheless fell to $592.6 million from $759.7 million. A $450 million pretax antitrust settlement charge was a major contributor. Third-quarter adjusted earnings also included a $22 million after-tax benefit from refunds of tariffs paid in prior periods; that benefit should not be extrapolated as a recurring margin driver.

ISRG Cash Flow Funds Investment and Buybacks

As of Sept. 30, cash, cash equivalents and investments totaled $6.80 billion, down from $9.03 billion at year-end 2025. During the third quarter the company repurchased 7.8 million shares for $2.94 billion, contributing to the reduction in available balances.

Operating cash flow for the first nine months reached $3.20 billion versus $2.14 billion a year earlier. Capital expenditures totaled $329 million, while year-to-date share repurchases reached $4.42 billion. Inventory investment and the recorded litigation accrual also influenced working capital and cash conversion.

Intuitive Surgical Updates Full-Year Procedure Outlook

For 2026, management expects worldwide da Vinci procedure growth of approximately 14% to 15%, with results closer to the midpoint. This compares with its previous guidance of 13.5% to 15.5%, also centered near the midpoint, implying a narrower rather than materially higher outlook.

The company projects an adjusted gross profit margin of 68.7% to 69.3%, versus the prior 68% to 69% range. The current forecast includes an estimated tariff impact equal to 0.9% of revenue, excluding refunds. Management continues to expect 11% to 13% adjusted operating expense growth, as investment in technology and commercialization continues.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a upward trend in estimates revision.

VGM Scores

At this time, Intuitive Surgical has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Intuitive Surgical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Published in